MARÍA PILAR
GARCÍA ALFONSO
Profesora asociada de Ciencias de la Salud
Hospital Clínico San Carlos de Madrid
Madrid, EspañaPublications en collaboration avec des chercheurs de Hospital Clínico San Carlos de Madrid (20)
2023
-
Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 2, pp. 379-388
2022
-
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)
European Journal of Cancer, Vol. 177, pp. 154-163
-
Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer
Cancer Biomarkers, Vol. 34, Núm. 2, pp. 201-210
2021
-
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231
-
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study
ESMO open, Vol. 6, Núm. 2, pp. 100062
2020
-
Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion
Clinical Colorectal Cancer, Vol. 19, Núm. 3, pp. 165-177
-
FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: The randomised phase III VISNÚ-1 trial
ESMO Open, Vol. 5, Núm. 6
-
Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology
Clinical and Translational Oncology, Vol. 22, Núm. 11, pp. 1976-1991
2019
-
Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: Retrospective analyses of two phase II randomised Spanish TTD trials
ESMO Open, Vol. 4, Núm. 6
-
Update of metastatic colorectal cancer metastases resection after FOLFIRI-aflibercept in oxaliplatin-refractory patients
Annals of Oncology, Vol. 30, pp. iv51-iv52
2018
-
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study
European Journal of Cancer, Vol. 101, pp. 263-272
-
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)
Oncologist, Vol. 23, Núm. 11, pp. 1271-e128
2015
-
Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer
Annals of Oncology, Vol. 26, Núm. 3, pp. 535-541
-
Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 17, Núm. 4, pp. 264-273
2013
-
Bevacizumab plus chemotherapy continued beyond first progression in patients withmetastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings
Annals of Oncology, Vol. 24, Núm. 9, pp. 2342-2349
2012
-
Guidelines for biomarker testing in colorectal carcinoma (CRC): A national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 14, Núm. 10, pp. 726-739
-
Recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica
Revista Espanola de Patologia
2011
-
Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain
Clinical and Translational Oncology, Vol. 13, Núm. 12, pp. 862-868
-
Treatment recommendations for metastatic colorectal cancer
Clinical and Translational Oncology, Vol. 13, Núm. 3, pp. 162-178
2010
-
Consensus document on the use of biosimilar granulocyte-colony stimulating factor for the correction of neutropenia associated in cancer patients
Farmacia Hospitalaria, Vol. 34, Núm. SUPPL. 1, pp. 45-50